metadata stringlengths 310 9.04k | data stringlengths 128 33.3k | criteria stringlengths 220 17.4k | NCT_ID stringlengths 11 11 ⌀ | __index_level_0__ int64 0 40.3k |
|---|---|---|---|---|
{
"NCT_ID" : "NCT01025778",
"Brief_Title" : "Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia",
"Official_title" : "Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies",
"Conditions" : ["... | #Study Description
Brief Summary
Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment. In other words it will be not possible to achieve remission using standard chemotherapy (primary resistance) or the... | #Eligibility Criteria:
Inclusion Criteria:
Target population
* Refractory acute lymphoblastic leukemia
* Chemoresistant isolated or combined bone marrow relapse
* Relapse after during/after conventional treatment
* Relapse >=6 months after allogeneic stem cell transplantation
* Primary induction fai... | NCT01025778 | 33,518 |
{
"NCT_ID" : "NCT01718691",
"Brief_Title" : "Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma",
"Official_title" : "Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untr... | #Study Description
Brief Summary
The purpose of this study is to assess the efficacy and safety of SyB L-0501 (two-day consecutive 90 mg/m2/day IV drip infusions) in combination with rituximab (375 mg/m2 IV drip infusion) on untreated, low-grade B cell non-Hodgkin's lymphoma and mantle cell lymphoma where hematopoiet... | #Eligibility Criteria:
Inclusion Criteria:
* Patients who are histopathologically confirmed to have the following cluster of differentiation 20 (CD20) positive low-grade B cell non-Hodgkin's lymphoma or mantle cell lymphoma by lymph node biopsy or evaluable tissue biopsy within 6 months before the registration WHO Cla... | NCT01718691 | 4,095 |
{
"NCT_ID" : "NCT01317940",
"Brief_Title" : "Nutrition and Body Composition in Acute Lymphoblastic Leukemia",
"Official_title" : "Nutrition and Body Composition in Acute Lymphoblastic Leukemia (Environment and Microenvironment in ALL #2)",
"Conditions" : ["Precursor Cell Lymphoblastic Leukemia-Lymphoma", "Vitamin D D... | #Study Description
Brief Summary
Many adolescents with acute lymphoblastic leukemia (ALL) have been found to have low bone density by the end of treatment. This can lead to long-term suffering in survivors due to poor bone health. Vitamin D is known to be associated with bone health and previous research has establis... | #Eligibility Criteria:
Inclusion Criteria:
GROUP A: Patients with newly diagnosed ALL
* Are greater than or equal to 10 years and less than or equal to 21 years at diagnosis of ALL
* Have a new diagnosis of untreated ALL classified as 'high risk' per NCI criteria (due to being greater than 10 years)
* Are beginning t... | NCT01317940 | 4,848 |
{
"NCT_ID" : "NCT00928798",
"Brief_Title" : "Topical Rapamycin for Fibrofolliculomas",
"Official_title" : "Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome",
"Conditions" : ["Birt-Hogg-Dubé Syndrome"],
"Interventions" : ["Drug: placebo", "Drug: Rapamycin"],
"Location_Countries" : ["Netherland... | #Study Description
Brief Summary
The purpose of the study is to determine whether topical application of rapamycin can lead to reduction in size and/or number of fibrofolliculomas in BHD patients and may prevent the growth of new ones. Secondary we evaluate rapamycin safety, formula acceptance and patient satisfactio... | #Eligibility Criteria:
Inclusion Criteria:
* Minimum age of 18 years.
* At least 10 facial fibrofolliculomas, histologically confirmed.
* Entered in a screening program and free of malignancy as determined during screening (already had a baseline MRI or CT-scan).
* Being able to understand instructions.
* Mutation sta... | NCT00928798 | 38,197 |
{
"NCT_ID" : "NCT00866918",
"Brief_Title" : "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia",
"Official_title" : "Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation",
"Co... | #Study Description
Brief Summary
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stop... | #Eligibility Criteria:
Inclusion Criteria:
* Patients must be newly diagnosed with a clinical diagnosis of acute promyelocytic leukemia initially by morphology (bone marrow or peripheral blood); bone marrow is highly preferred but in cases where marrow cannot be obtained at diagnosis, peripheral blood will be accepted... | NCT00866918 | 20,128 |
{
"NCT_ID" : "NCT01969448",
"Brief_Title" : "Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction",
"Official_title" : "A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction",
"Condi... | #Study Description
Brief Summary
The investigators hypothesize that nipple-areola skin sparing mastectomy (NASSM) performed through an inframammary incision has a superior blood supply relative to a lateral oblique incision. Moreover, by minimizing complications and optimizing aesthetic outcomes, the investigators be... | #Eligibility Criteria:
Inclusion Criteria:
* Patient must be scheduled to undergo either a single or bilateral elective nipple-areola skin sparing mastectomy (NASSM) procedure with planned immediate reconstruction.
* Patient must be 18 years or older.
* Karnofsky Performance Scale of at least 80%.
* Patient must be ab... | NCT01969448 | 7,030 |
{
"NCT_ID" : "NCT01367652",
"Brief_Title" : "Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions",
"Official_title" : "A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions",
"Conditions" : ["Breast Cancer"],
"Interventions" : ["Dr... | #Study Description
Brief Summary
The objective of this study was to prove the bioequivalence of Letrozole Tablet under fasted conditions.
#Intervention
- DRUG : Letrozole
- 2.5 mg tablet
- Other Names :
- Femara
- DRUG : Letrozole
- 2.5 mg Tablet
- Other Names :
- Femara | #Eligibility Criteria:
Inclusion Criteria:
* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion Criteria:
* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of ... | NCT01367652 | 28,401 |
{
"NCT_ID" : "NCT01957735",
"Brief_Title" : "BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors",
"Official_title" : "A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosus... | #Study Description
Brief Summary
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with chemotherapy (treatment... | #Eligibility Criteria:
Inclusion Criteria:
* The patient has a histologically confirmed solid tumor that is metastatic or unresectable for which standard measures do not exist or are no longer effective. (Patients with primary brain cancer or lymphoma are permitted. Patients with brain metastases are allowed if whole ... | NCT01957735 | 13,453 |
{
"NCT_ID" : "NCT01442285",
"Brief_Title" : "The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)",
"Official_title" : "The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)",
"Conditions" : ["Cancer", "Distress"],
"Interventions" : ["Behavioral: personalized, motivational messages"]... | #Study Description
Brief Summary
The purpose of this study is to understand more about meeting the psychosocial needs of people who have cancer.
Detailed Description
The investigators are interested in the feasibility of using computer assisted screening and assessment to meet the psychosocial needs of people with ... | #Eligibility Criteria:
Inclusion Criteria:
* cancer diagnosis
Sex :
ALL
Ages :
- Minimum Age : 18 Years
- Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT
Accepts Healthy Volunteers:
No
| NCT01442285 | 31,032 |
{
"NCT_ID" : "NCT02939300",
"Brief_Title" : "Ipilimumab and Nivolumab in Leptomeningeal Metastases",
"Official_title" : "Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases",
"Conditions" : ["Leptomeningeal Carcinomatosis"],
"Interventions" : ["Drug: Ipilimumab", "Drug: Nivolumab"],
"Location_Co... | #Study Description
Brief Summary
This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases.
The names of the study interventions involved in this study are:
* Ipilimumab
* Nivolumab
Detailed Description
This research study is a Phase II clinical trial.
Resea... | #Eligibility Criteria:
Inclusion Criteria:
* Participants must have histologically or cytologically confirmed disease from any solid tumor
* Age >=18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status <=2 (Karnofsky >=60%)
* Life expectancy of greater than 3 weeks
* Participants must have normal org... | NCT02939300 | 28,738 |
{
"NCT_ID" : "NCT02834364",
"Brief_Title" : "BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)",
"Official_title" : "LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation",
"Conditions" : ["Relapsed or Refractory Multiple Myeloma",... | #Study Description
Brief Summary
Trial for patients with refractory multiple myeloma after failure of at least two treatment regimens and with BRAFV600E/K Mutation to evaluate the efficacy of the kinase inhibitors Encorafenib (LGX818 in) combination with Binimetinib (MEK162).
Detailed Description
An open-label, sin... | #Eligibility Criteria:
Inclusion Criteria:
* Patient has provided a signed study Informed Consent Form prior to any study-specific procedure and is able to comply with protocol requirements
* Patients with multiple myeloma,relapsed or refractory after failure of two or more lines of systemic treatments. All patients m... | NCT02834364 | 23,542 |
{
"NCT_ID" : "NCT00412503",
"Brief_Title" : "Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents",
"Official_title" : "Phase 1 Study of Temozolomide Associated With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents",
"Conditi... | #Study Description
Brief Summary
Long term survival can now be achieved in 75% of cases of pediatric cancers. However, some types of tumors (ie CNS tumors) or advanced stages (metastatic sarcomas/neuroblastomas) cannot be cured by any treatment. Thus, evaluation of new drugs or combinations are strongly needed. The r... | #Eligibility Criteria:
Inclusion Criteria:
* histologically documented malignant tumor
* refractory or relapsing after conventional treatments and for which there is no curative treatment available
* life expectancy > 8 weeks
* no significant co-morbidity (NCI-CTC < 2)
* No organ toxicity
* no chemotherapy within the ... | NCT00412503 | 21,807 |
{
"NCT_ID" : "NCT01740323",
"Brief_Title" : "Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy",
"Official_title" : "Meriva for Treatment-induced Inflammation and Fatigue in Women With Breast Cancer",
"Conditions" : ["Breast Cancer"],
"Interventions" : ["Dr... | #Study Description
Brief Summary
The main purpose of the investigation is to determine if curcumin reduces NF-kB DNA binding and ultimately its downstream mediator IL-6 in patients receiving XRT for their breast cancer after having completed chemotherapy. Patients who have received prior chemotherapy will be eligible... | #Eligibility Criteria:
Inclusion Criteria:
* Female breast cancer patients over the age of 18 will be recruited for this study. Patients enrolled in the study will meet standard criteria for whole breast XRT.
Exclusion Criteria:
* Subjects will be excluded for a number of medical conditions that are contraindication... | NCT01740323 | 21,086 |
{
"NCT_ID" : "NCT04055142",
"Brief_Title" : "Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males",
"Official_title" : "A Phase III, Randomized, One-site, Pilot, Op... | #Study Description
Brief Summary
This study wants to demonstrate the non-inferiority in terms of efficacy and safety of treatment with cidofovir (1%) in topical ointment or topical sinecatechins (10%) ointment versus electrocoagulation (control group) for the treatment of high-grade anal intraepithelial neoplasia (HG... | #Eligibility Criteria:
Inclusion Criteria:
* Men who have sex with men, older or same than 18 years.
* HIV-1 positive men.
* High grade anal intraepithelial neoplasia recognised by biopsy during 12 months previous to study.
* Informed consent is signed voluntarily.
Exclusion Criteria:
* Patient with any disease or c... | NCT04055142 | 25,883 |
{
"NCT_ID" : "NCT00116441",
"Brief_Title" : "Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma",
"Official_title" : "Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line",
"Conditi... | #Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
#Intervention
- BIOLOGICAL : Therapeutic Cellular Vaccine, GM-CSF Producing | #Eligibility Criteria:
Inclusion Criteria:
* De novo multiple myeloma
* ECOG 0 <= age <= 2
* No serious co-morbid illnesses and adequate organ function
* > 4 weeks from systemic steroids
Exclusion Criteria:
* No existing secondary malignancies and no history of secondary malignancies in the past 5 years
* No active ... | NCT00116441 | 19,366 |
{
"NCT_ID" : "NCT04232059",
"Brief_Title" : "The Effect of Different Ventilation Strategies on Cerebral Oxygenation Using Near Infrared Spectroscopy (NIRS) in Pediatrics Undergoing Posterior Fossa Tumor Surgery",
"Official_title" : "The Effect of Different Ventilation Strategies on Cerebral Oxygenation Using Near Infr... | #Study Description
Brief Summary
The aim of this study is to evaluate the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
Detailed Description
Introduction:
Hyperventilation has been use... | #Eligibility Criteria:
Inclusion Criteria:
* Age : 1 <= age <= 6 old
* Both sexes
* ASA I-II
* scheduled for posterior fossa tumor resection.
Exclusion Criteria:
* Age < 1 year or > 6 years
* Comorbid condition (ASA classification > II)
* patient with anemia (Hb <10 g/dl)
* Emergency surgery
* Patients wi... | NCT04232059 | 29,459 |
{
"NCT_ID" : "NCT03167762",
"Brief_Title" : "Photographing the Skin During Photodynamic Therapy",
"Official_title" : "Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy",
"Conditions" : ["Basal Cell Carcinoma", "Bowen's Disease"],
"Interventions" : ["Device: Fluorescence and thermal ... | #Study Description
Brief Summary
Photodynamic therapy (PDT) is used to treat some types of sun-damaged skin and low-grade forms of growths. A cream is applied to the skin, and the chemical in this cream is absorbed in to the skin and converted in to a 'photosensitiser'. This photosensitiser is fluorescent, meaning th... | #Eligibility Criteria:
Inclusion Criteria:
* 1. Patients presenting with superficial BCC or Bowen's disease (one or two lesions and diagnosed either clinically or histologically and untreated or having had no treatment for 4 months or longer) 2. Adult males and females, >18 years only 3. Capable of giving informed con... | NCT03167762 | 4,661 |
{
"NCT_ID" : "NCT03183765",
"Brief_Title" : "Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts",
"Official_title" : "Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Random... | #Study Description
Brief Summary
Warts are benign epidermal tumors caused by human papilloma virus, which are epitheliotropic non-enveloped double stranded DNA viruses. Transmission of warts occurs from direct person-to-person contact or indirectly by fomites . Warts appear in various forms including verruca vulgaris... | #Eligibility Criteria:
Inclusion Criteria:
* Patients should have multiple common or plantar warts.
* No concurrent systemic or topical treatment of warts
Exclusion Criteria:
* patients under 16 years.
* Patients with fever or signs of any inflammation or infection.
* Patients with other types of warts.
* Patien... | NCT03183765 | 25,419 |
{
"NCT_ID" : "NCT01983592",
"Brief_Title" : "An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy",
"Official_title" : "An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy",
"Conditions" : ["Fatigue", "Effects of Chemotherapy"],
"Interventions" : [... | #Study Description
Brief Summary
Fatigue is frequently identified as one of the most troublesome symptoms in cancer patients and there are very few conventional therapies which can address the symptom of fatigue in patients who are undergoing cancer treatment.
This study will be testing whether the administration of... | #Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with any type of cancer. Patient may have newly diagnosed, relapsed or a second malignant disease.
* Receiving any type of cytotoxic chemotherapy with 6 or more cycles post study enrollment administered intermittently every two or three weeks with no planned radia... | NCT01983592 | 4,569 |
{
"NCT_ID" : "NCT00355472",
"Brief_Title" : "Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL",
"Official_title" : "Phase I Dose Escalation Study of KW-0761 in Patients With Relapsed Adult T-Cell Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL)",
"Conditions" : ["Adult T-Cell Leukemia... | #Study Description
Brief Summary
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
Detailed Description
This is a Phase I open-label dose escalation study of KW-0761 in relapsed patients with C... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed diagnosis of a CCR4-positive ATL and PTCL that is any of the following:
A. ATL (Adult T-Cell Leukemia-Lymphoma)
* Seropositive for anti-Human T-lymphotrophic Virus type-I (HTLV-I) antibody;
* Acute, Lymphoma, or Chronic phase with high-risk factor... | NCT00355472 | 16,032 |
{
"NCT_ID" : "NCT03796819",
"Brief_Title" : "Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma",
"Official_title" : "Impact of Routine Lymphadenectomy on Prognosis of Patients Undergoing Curative Resection for Intrahepatic Cholangiocarcinoma",
"Conditions" : ["Intrahepatic Cholangiocarcinoma"],
"Interventi... | #Study Description
Brief Summary
The role of routine lymphadenectomy (LND) in the surgical treatment of intrahepatic cholangiocarcinoma (ICC) remains controversial. The investigators' multi-institutional retrospective study have showed an increasing adoption of LND among patients undergoing curative resection for ICC... | #Eligibility Criteria:
Inclusion Criteria:
* Patients diagnosed with intrahepatic cholangiocarcinoma by imaging or biopsy
* The tumor is limited in the liver with no distant metastasis, and the primary disease is resectable
* Preoperative imaging (e.g. CT, MRI, PET-CT, etc.) and intraoperative exploration found no nod... | NCT03796819 | 18,444 |
{
"NCT_ID" : "NCT03001882",
"Brief_Title" : "An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)",
"Official_title" : "An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination ... | #Study Description
Brief Summary
The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
#Intervention
- BIOLOGI... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease
* Measurable disease by CT or MRI
* Must have full activity or, if limited, must be able to walk ... | NCT03001882 | 2,225 |
{
"NCT_ID" : "NCT01295632",
"Brief_Title" : "Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)",
"Official_title" : "Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Dou... | #Study Description
Brief Summary
This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752. In Part A of the study, the preliminary maximum tolerated dose (MTD) of the drug combinations will be found by giving sequentially higher doses of the study drugs. An expansion cohort of partic... | #Eligibility Criteria:
Inclusion Criteria:
Part A of the Study:
Participant must have a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist. Non Hodgkin Lymphoma (NHL) part... | NCT01295632 | 29,689 |
{
"NCT_ID" : "NCT00836186",
"Brief_Title" : "Cytokine Expression During Radiation for Breast Cancer",
"Official_title" : "Cytokine Expression During Radiation for Breast Cancer",
"Conditions" : ["Breast Cancer"],
"Interventions" : ["Radiation: Radiation therapy"],
"Location_Countries" : ["United States"],
"Study_D... | #Study Description
Brief Summary
To assess the magnitude and frequency of changes in chemo/cytokine expression in women receiving radiation treatment. To asses the impact of race/ethnicity on the magnitude and frequency of changes in chemo/cytokine expression during radiation therapy for breast cancer. And finally to... | #Eligibility Criteria:
INCLUSION CRITERIA:
* Patient must be 18 years or older
* Patients must have histologically confirmed (by routine H&E staining) adenocarcinoma of the breast any T, any N, M0 disease
* Patients must have undergone a segmental mastectomy (SM) with a level I and ll axillary dissection or sentinel l... | NCT00836186 | 19,096 |
{
"NCT_ID" : "NCT04117750",
"Brief_Title" : "Impact of Vitamin D Supplementation on Cardiometabolic Status and Androgen Profile in Polycystic Ovary Syndrome",
"Official_title" : "Impact of Vitamin D Supplementation on the Cardiometabolic Status and Androgen Profile in Women With Polycystic Ovary Syndrome: Placebo-Cont... | #Study Description
Brief Summary
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of reproductive, endocrine and metabolic functions. Vitamin D has an influence on metabolic and reproductive functions. This study was designed to explore the levels of free 25 hydroxy cholecalciferol \[25(OH) D\] in PCOS pa... | #Eligibility Criteria:
Inclusion Criteria:
* women with PCO. The diagnosis of PCOS was based on the 2004 revised Rotterdam criteria
* women must be able to swallow tablets
Exclusion Criteria:
* a history of hyperandrogenic states (such as nonclassic congenital adrenal hyperplasia, androgen-secreting tumors, Cushing'... | NCT04117750 | 22,719 |
{
"NCT_ID" : "NCT00420160",
"Brief_Title" : "Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?",
"Official_title" : "Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?",
"Conditions" : ["Lung Cancer", "Heart Disease", "COPD"],
"Interventions" : ["Behavioral: Smoking c... | #Study Description
Brief Summary
This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard smoking cessation treatment plus equivalent contact control among ... | #Eligibility Criteria:
Inclusion Criteria:
* Healthy sedentary smokers (> 4 per day for at least one year)
* Ages 18 <= age <= 65
* Must be able to give informed consent
* Must live in the area for the next 3 months
* Willing to use the nicotine patch to attempt smoking cessation
* Must receive consent to participate ... | NCT00420160 | 6,386 |
{
"NCT_ID" : "NCT00268671",
"Brief_Title" : "Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)",
"Official_title" : "Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
"Conditions" : ... | #Study Description
Brief Summary
Study Objectives:
* To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
* To determine the response rate of the recommende... | #Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed (of original primary tumor) locoregional recurrent and/or metastatic following prior radiotherapy and/or surgery and not amenable to further curative local therapy for SCCHN
* Measurable disease as defined by at least the longest diameter measured a... | NCT00268671 | 33,414 |
{
"NCT_ID" : "NCT01947166",
"Brief_Title" : "Pancreatic Resection, Malnutrition and Readmission",
"Official_title" : "Pancreatic Resection, Malnutrition, and Readmission: Assessment and Prevention",
"Conditions" : ["Pancreatic Cancer", "Malnutrition"],
"Location_Countries" : ["United States"],
"Study_Design" : {
"S... | #Study Description
Brief Summary
The Whipple procedure is associated with increased readmission rates for infection, pancreatic leak, and failure to thrive/malnutrition. The purpose of this study is to develop an evidence based perioperative nutrition plan to improve patient outcomes. The study has two specific aims ... | #Eligibility Criteria:
Inclusion Criteria:
* Adult patients (>18 years)at Duke Cancer Center
* Malignant pancreatic disease, undergoing surgical resection with pancreaticoduodenectomy (Whipple)
* Able to read and speak English.
Exclusion Criteria:
* Patients receiving preoperative enteral nutrition
* Inability to to... | NCT01947166 | 2,141 |
{
"NCT_ID" : "NCT04552405",
"Brief_Title" : "Preventive Anti-inflammatory Diet to Reduce Gastro-intestinal Inflammation in FAP Patients: a Prospective Pilot Study",
"Official_title" : "Preventive Anti-inflammatory Diet to Reduce Gastro-intestinal Inflammation in FAP Patients: a Prospective Pilot Study",
"Conditions" ... | #Study Description
Brief Summary
Preventive anti-inflammatory diet to reduce gastro-intestinal inflammation in FAP patients: a prospective pilot study
Detailed Description
a prospective pilot study
#Intervention
- DIETARY_SUPPLEMENT : Anti-inflammatory Diet
- FAP individuals followed for 3 months a low-inflamma... | #Eligibility Criteria:
Inclusion Criteria:
* FAP patients carrying mutations in APC gene, submitted to prophylactic total colectomy/IRA (with rectum preservation) and that participate to the regular endoscopic surveillance program at IRCCS-INT.
Exclusion Criteria:
* FAP patients taking NSAIDs and/or Omega 3
* Patie... | NCT04552405 | 39,177 |
{
"NCT_ID" : "NCT01531894",
"Brief_Title" : "Continuation Study of the Oral AKT Inhibitor GSK2110183",
"Official_title" : "An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies",
"Conditions" : ["Cancer"],
"Interventions" : ["Drug: GSK2110183... | #Study Description
Brief Summary
This multicenter, non-randomized, open-label, treatment continuation or 'rollover' study was designed to provide continued access to eligible subjects who had previously participated in a GSK2110183 study (parent study) sponsored by GlaxoSmithKline (GSK) or another research organizati... | #Eligibility Criteria:
Inclusion Criteria:
* Has provided signed informed consent for this study.
* Is currently participating in a GSK2110183 study (monotherapy or in combination with an approved anti-cancer agent) sponsored by GSK or by another research organization working on behalf of GSK.
* Currently benefitting ... | NCT01531894 | 139 |
{
"NCT_ID" : "NCT02115139",
"Brief_Title" : "GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases",
"Official_title" : "A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases",
... | #Study Description
Brief Summary
Ipilimumab adds a clinical benefit to radiation therapy in patients with melanoma metastatic to the brain.
Melanoma is the third most common cancer causing brain metastases, after cancers of the lung and breast, which appears to reflect the relative propensity of melanoma to metastas... | #Eligibility Criteria:
Inclusion Criteria:
* Willing and able to give written informed consent.
* Histologic diagnosis of melanoma.
* First episode of radiological evidence of brain metastases
* Be over the age of 18 years
* Radiation Therapy Oncology Group-recursive partitioning analysis (RTOG-RPA) class 2
* Karnofsk... | NCT02115139 | 11,836 |
{
"NCT_ID" : "NCT01530581",
"Brief_Title" : "Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation",
"Official_title" : "A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patie... | #Study Description
Brief Summary
This is a Randomized Multicentre study Comparing GCSF Mobilized Peripheral Blood and GCSF stimulated Bone Marrow in Patients undergoing matched sibling Transplantation for Haematologic Malignancies.
#Intervention
- PROCEDURE : G-PB Transplant
- G-PB Transplant
- PROCEDURE : G-BM T... | #Eligibility Criteria:
Inclusion Criteria:
* Recipient must
1. Be between the ages of 16 and 65 years
2. Have one of the following hematologic malignancies:
* Acute myeloid leukemia (de novo, secondary or therapy related) in untreated 1st relapse or in remission or with evidence of molecular relapse but bla... | NCT01530581 | 13,748 |
{
"NCT_ID" : "NCT01579357",
"Brief_Title" : "Pharmacokinetics and Metabolic Activation of Capecitabine",
"Official_title" : "Pharmacokinetics and Metabolic Activation of Capecitabine When Given Concomitantly With Oxaliplatin and the Monoclonal Antibody Cetuximab",
"Conditions" : ["Metastatic Colorectal Cancer"],
"In... | #Study Description
Brief Summary
The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).
#Intervention
- OTHER : blood samples
- Draw blood samp... | #Eligibility Criteria:
Inclusion Criteria selected:
* signed written informed consent
* male or female > 18 years
* K-ras wild type adenocarcinoma of the colon or rectum
* metastatic colorectal carcinoma
* ECOG <= 2
Exclusion Criteria selected:
* brain metastasis
* previous chemotherapy
* stage 3 or 4 heart failure
... | NCT01579357 | 6,500 |
{
"NCT_ID" : "NCT00577876",
"Brief_Title" : "Assessment of the Functional Significance of Accessory Pudendal Arteries",
"Official_title" : "Assessment of the Functional Significance of Accessory Pudendal Arteries",
"Conditions" : ["Prostate Cancer"],
"Interventions" : ["Procedure: Trimix Injection with Doppler Ultra... | #Study Description
Brief Summary
For patients with Prostate Cancer advances in medical technology have enabled us to identify 'accessory' (additional) pudendal arteries (called APA) while performing a laparoscopic radical prostatectomy (a scope with a video camera is used during the surgery). APAs running near the pr... | #Eligibility Criteria:
Inclusion Criteria:
* They have selected a LRP, with or without robotic assistance, by Jonathan Colelman, MD, Bertrand Guillonneau, MD, Vincent Laudone, MD, Raul Parra, MD, or Karim Touijer MD for definitive treatment of their prostate cancer after a full discussion of treatment options.
Exclus... | NCT00577876 | 5,329 |
{
"NCT_ID" : "NCT02065154",
"Brief_Title" : "Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis",
"Official_title" : "Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Don... | #Study Description
Brief Summary
The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD). The primary objective is to determine the incidence of grade II-IV acute GVHD following Allogeneic (allo) He... | #Eligibility Criteria:
Inclusion Criteria:
* Disease Criteria: patients must meet diagnostic criteria of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), myelodysplastic syndrome (MDS... | NCT02065154 | 32,715 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 5